Family history and the risk of prostate cancer

Prostate

17, 337-347

DOI: 10.1002/pros.2990170409

Citation Report

#	Article	IF	CITATIONS
1	Familial Patterns of Prostate Cancer: A Case-Control Analysis. Journal of Urology, 1991, 146, 1305-1307.	0.2	201
2	Prostate Cancer: A Current Perspective. Epidemiologic Reviews, 1991, 13, 200-227.	1.3	233
3	Metastatic Models and Molecular Genetics of Prostate Cancer. Journal of the National Cancer Institute, 1992, 84, 914-915.	3.0	6
4	Mendelian inheritance of familial prostate cancer Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 3367-3371.	3.3	653
5	Diagnosis of Prostate Cancer: A Personal View. Journal of Urology, 1992, 147, 830-832.	0.2	32
7	Molecular Genetics of Tumor Suppressor Genes in Prostate Carcinoma: the Challenge and the Promise Ahead. Journal of Urology, 1992, 147, 808-809.	0.2	10
8	A Screening Study of Prostate Cancer in High Risk Families. Journal of Urology, 1992, 148, 826-827.	0.2	64
9	Chromosomal abnormalities and related events in prostate cancer. Human Pathology, 1992, 23, 368-380.	1.1	116
10	Tumour Suppressor Genes in Urinary Tract Oncology. British Journal of Urology, 1992, 70, 585-590.	0.1	14
11	Castration-like effects on the human prostate of a $5\hat{l}_{\pm}$ -reductase inhibitor, finasteride. Journal of Cellular Biochemistry, 1992, 50, 109-112.	1.2	19
12	The association of benign prostatic hyperplasia and cancer of the prostate. Cancer, 1992, 70, 291-301.	2.0	175
13	Recessive oncogenes. Cancer, 1993, 71, 1179-1186.	2.0	27
14	Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer, 1993, 71, 933-938.	2.0	707
15	Molecular epidemiology studies of cancer in families. British Journal of Cancer, 1993, 68, 217-219.	2.9	16
16	Prostate-Specific Antigen, Digital Rectal Examination, and Transrectal Ultrasonography: Their Roles in Diagnosing Early Prostate Cancer. Mayo Clinic Proceedings, 1993, 68, 297-306.	1.4	48
17	Screening for prostate cancer: Enthusiasm. Urology, 1993, 42, 113-115.	0.5	41
19	Hereditary Prostate Cancer: Epidemiologic and Clinical Features. Journal of Urology, 1993, 150, 797-802.	0.2	519
20	Hereditary Aspects of Urologic Cancer. Surgical Oncology Clinics of North America, 1994, 3, 609-629.	0.6	1

#	Article	IF	Citations
21	Genetics of urological cancers. British Medical Bulletin, 1994, 50, 698-707.	2.7	3
22	PROSTATE CARCINOMA. Annual Review of Medicine, 1994, 45, 351-359.	5.0	9
23	Do Diet and Androgens Alter Prostate Cancer Risk via a Common Etiologic Pathway?. Journal of the National Cancer Institute, 1994, 86, 252-255.	3.0	129
25	Screening for Prostate Cancer. JAMA - Journal of the American Medical Association, 1994, 272, 773.	3.8	186
27	Prostate adenocarcinoma in men younger than 50 years. A retrospective review of 151 patients. Cancer, 1994, 74, 1768-1777.	2.0	64
28	Genetic epidemiology of cancer: A multidisciplinary approach. Genetic Epidemiology, 1994, 11, 235-254.	0.6	12
29	Prostate cancer. Current Problems in Cancer, 1994, 18, 298-357.	1.0	3
30	Review of the role of androgenic hormones in the epidemiology of benign prostatc hyperplasia and prostate cancer. Urology, 1994, 43, 892-899.	0.5	92
31	Receptivity of african-american men to prostate cancer screening. Urology, 1994, 43, 480-487.	0.5	64
32	Observations on the epidemiology and natural history of prostate cancer. Urology, 1994, 44, 2-8.	0.5	29
33	Prostate-Specific Antigen: Critical Issues for the Practicing Physician. Mayo Clinic Proceedings, 1994, 69, 59-68.	1.4	45
34	The inherited component of cancer. British Medical Bulletin, 1994, 50, 527-535.	2.7	55
35	Applications of the Case-Control Method in Genetic Epidemiology. Epidemiologic Reviews, 1994, 16, 134-150.	1.3	70
36	Studies of Genetic Factors in Prostate Cancer in a Twin Population. Journal of Urology, 1994, 152, 1484-1487.	0.2	132
37	Systematic Sextant Biopsies in 651 Patients Referred for Prostate Evaluation. Journal of Urology, 1994, 151, 99-102.	0.2	134
38	Somatic Allelic Loss at the DCC, APC, nm23-H1 and P53 Tumor Suppressor Gene Loci in Human Prostatic Carcinoma. Journal of Urology, 1994, 151, 1073-1077.	0.2	91
39	Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men. Journal of Urology, 1994, 151, 1283-1290.	0.2	1,337
40	Clinical Experience of the Detection of Prostate Cancer in Patients with Benign Prostatic Hyperplasia Treated with Finasteride. Journal of Urology, 1994, 151, 1296-1300.	0.2	22

#	ARTICLE	IF	Citations
41	Family History and Prostate Cancer Risk in Black, White, and Asian Men in the United States and Canada. American Journal of Epidemiology, 1995, 141, 732-740.	1.6	236
42	Male genital cancers. Cancer, 1995, 75, 295-315.	2.0	42
43	Epidemiologic Characteristics of Prostate Cancer. Cancer, 1995, 75, 1766-1777.	2.0	92
44	Does the racial-ethnic variation in prostate cancer risk have a hormonal basis?. Cancer, 1995, 75, 1778-1782.	2.0	53
45	Frontiers in prostate cancer. Telomeres and chaos. Cancer, 1995, 75, 2027-2035.	2.0	13
46	Prostate cancer risk in U.S. blacks and whites with a family history of cancer. International Journal of Cancer, 1995, 60, 361-364.	2.3	140
47	Gene amplifications in advanced-stage human prostate cancer. Urological Research, 1995, 22, 343-347.	1.5	33
48	The impact of family history on early detection of prostate cancer. Nature Medicine, 1995, 1, 99-101.	15.2	156
49	Differences in cancer incidence, mortality, and survival between African Americans and whites Environmental Health Perspectives, 1995, 103, 275-281.	2.8	58
51	Risk of Cancer in Relatives of Prostate Cancer Probands. Journal of the National Cancer Institute, 1995, 87, 991-996.	3.0	134
52	Dietary Fat and Risk of Prostate Cancer. Journal of the National Cancer Institute, 1995, 87, 1427-1428.	3.0	15
53	Re: Familial Clustering of Breast and Prostate Cancers and Risk of Postmenopausal Breast Cancer. Journal of the National Cancer Institute, 1995, 87, 536-537.	3.0	1
54	Radical prostatectomy in men less than 50 years old. Urologic Oncology: Seminars and Original Investigations, 1995, 1, 80-83.	0.8	21
55	Reported family history of cancer in 1,271 prostate cancer cases and 1,909 controls. Urologic Oncology: Seminars and Original Investigations, 1995, 1, 240-245.	0.8	9
56	Hypothesis: The prenatal origins of prostate cancer. Human Pathology, 1995, 26, 1291-1292.	1.1	21
57	Should medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? part I: Framing the debate. Urology, 1995, 46, 2-13.	0.5	33
58	Using prostate-specific antigen to eliminate unnecessary diagnostic tests: Significant worldwide economic implications. Urology, 1995, 46, 26-33.	0.5	34
59	Original Articles: Prostate Cancer: Pathological Features of Hereditary Prostate Cancer. Journal of Urology, 1995, 153, 987-992.	0.2	122

#	Article	IF	Citations
60	Familial Aspects of Prostate Cancer: A Case Control Study. Journal of Urology, 1995, 154, 2100-2102.	0.2	77
61	Editorial: Prostate Cancer. Journal of Urology, 1995, 154, 422-423.	0.2	0
62	HOW IS INDIVIDUAL RISK FOR PROSTATE CANCER ASSESSED?. Hematology/Oncology Clinics of North America, 1996, 10, 537-548.	0.9	15
63	Clinical and Pathological Features of Hereditary Prostate Cancer. Journal of Urology, 1996, 155, 1841-1843.	0.2	75
64	PROSTATE CANCER SCREENING. Medical Clinics of North America, 1996, 80, 83-98.	1.1	7
65	RADIOLOGIC IMAGING IN CANCER. Medical Clinics of North America, 1996, 80, 201-218.	1.1	0
66	Epidemiology of prostate cancer: molecular and environmental clues. Urology, 1996, 48, 676-683.	0.5	40
67	Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search. Science, 1996, 274, 1371-1374.	6.0	717
68	Welchen Einfluß hat die Einführung des Prostata spezifischen Antigens auf die Diagnostik des organbegrenzten Prostatakarzinoms. Der Urologe Ausg B, 1996, 36, 266-269.	0.1	0
69	REICAP: Prospective Epidemiologic Study of Prostate Cancer in Italy. European Urology, 1996, 30, 2-6.	0.9	28
70	Healthcare Resources Should Be Targeted to Chemoprevention in Prostate Cancer: The Argument For. European Urology, 1996, 29, 13-16.	0.9	0
71	Epidemiology of Prostate Cancer. European Urology, 1996, 30, 281-295.	0.9	82
72	Prospects for prostatic cancer incidence and treatment by the year 2000. Journal of Developmental and Physical Disabilities, 1996, 19, 1-10.	3.6	4
73	DNA methylation, molecular genetic, and linkage studies in prostate cancer. Prostate, 1996, 29, 36-44.	1.2	29
74	Familial prostate cancer in sweden: A nationwide register cohort study., 1996, 77, 138-143.		114
75	Factors associated with intention to undergo annual prostate cancer screening among African American men in Philadelphia. Cancer, 1996, 78, 471-479.	2.0	91
76	Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer., 1996, 69, 110-113.		34
77	Nutrition and prostate cancer. Cancer Causes and Control, 1996, 7, 83-94.	0.8	184

#	Article	IF	Citations
78	Case-control study of risk factors for prostate cancer. British Journal of Cancer, 1996, 74, 1682-1686.	2.9	75
79	Genetic Basis and Clonal Evolution of Human Prostate Cancer. Advances in Cancer Research, 1996, 68, 225-255.	1.9	55
80	Family History and Prostate Cancer Risk. American Journal of Epidemiology, 1996, 144, 1041-1047.	1.6	120
81	Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. British Journal of Urology, 1997, 79, 8-14.	0.1	40
82	Family History and Risk of Fatal Prostate Cancer. Epidemiology, 1997, 8, 653.	1.2	75
83	Is Infant Immunization a Risk Factor for Childhood Asthma or Allergy?. Epidemiology, 1997, 8, 678.	1.2	130
84	Characteristics of Prostate Cancer in Families Potentially Linked to the Hereditary Prostate Cancer 1 (HPC1) Locus. JAMA - Journal of the American Medical Association, 1997, 278, 1251.	3.8	124
85	Segregation Analysis of Prostate Cancer in Sweden: Support for Dominant Inheritance. American Journal of Epidemiology, 1997, 146, 552-557.	1.6	154
87	CLINICAL GUIDELINE: PART 1: Early Detection of Prostate Cancer: Part I. Annals of Internal Medicine, 1997, 126, 394.	2.0	156
88	The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 3320-3323.	3.3	754
89	Association of Prostate Cancer Risk With Genetic Polymorphisms in Vitamin D Receptor and Androgen Receptor. Journal of the National Cancer Institute, 1997, 89, 166-170.	3.0	519
90	PROSTATE CANCER SCREENING AND MANAGEMENT. Medical Clinics of North America, 1997, 81, 801-822.	1.1	8
91	Prostate Cancer in Nigerians: Facts and Nonfacts. Journal of Urology, 1997, 157, 1340-1343.	0.2	87
92	Recent Developments in the Epidemiology of Prostate Cancer. European Journal of Cancer, 1997, 33, 340-347.	1.3	71
93	The risk of malignant tumours in first-degree relatives of men with early onset prostate cancer: A population-based cohort study. European Journal of Cancer, 1997, 33, 2237-2240.	1.3	35
94	Molecular carcinogenesis of prostate cancer: Potential clinical relevance and nursing implications. Seminars in Oncology Nursing, 1997, 13, 99-107.	0.7	3
95	Prostate cancer diagnosis and management. Lancet, The, 1997, 349, 1681-1687.	6.3	86
96	Linkage Analysis of 49 High-Risk Families Does Not Support a Common Familial Prostate Cancerâ€"Susceptibility Gene at 1q24-25. American Journal of Human Genetics, 1997, 61, 347-353.	2.6	114

#	ARTICLE	IF	CITATIONS
98	Familial prostate cancer studies in Utah. British Journal of Urology, 1997, 79, 15-20.	0.1	64
99	Environmental and genetic factors: a possible link with prostate cancer. British Journal of Urology, 1997, 79, 35-41.	0.1	16
100	No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. British Journal of Cancer, 1997, 76, 992-1000.	2.9	34
101	Family studies and the evidence for genetic susceptibility to prostate cancer. Seminars in Cancer Biology, 1997, 8, 45-51.	4.3	11
102	BRCA2 mutation in Icelandic prostate cancer patients. Journal of Molecular Medicine, 1997, 75, 758-761.	1.7	127
103	The aetiology and pathogenesis of prostate cancer. Clinical Oncology, 1997, 9, 213-218.	0.6	20
104	Family history: A comprehensive genetic risk assessment method for the chronic conditions of adulthood., 1997, 71, 315-324.		223
105	Heredity and prostate cancer: A study of World War II veteran twins. , 1997, 33, 240-245.		134
106	Family history facilitates the early diagnosis of prostate carcinoma., 1997, 80, 1871-1874.		48
107	Familial Prostate Cancer in Japan. International Journal of Urology, 1998, 5, 138-145.	0.5	16
108	Familial Prostate Cancer in Four Brothers. International Journal of Urology, 1998, 5, 386-390.	0.5	1
109	Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. British Journal of Cancer, 1998, 78, 1430-1433.	2.9	29
110	Prostate and Bladder Cancer Screening. Journal of the American College of Surgeons, 1998, 186, 63-74.	0.2	12
111	Recent advances in basic and clinical prostate cancer research. Cancer, 1998, 83, 1730-1733.	2.0	0
112	Familial prostate cancer and possible associated malignancies: Nation-wide register cohort study in Sweden., 1998, 78, 293-297.		32
113	No difference in survival between sporadic, familial and hereditary prostate cancer. BJU International, 1998, 82, 564-567.	1.3	47
114	Three pedigrees of hereditary prostate cancer. International Journal of Clinical Oncology, 1998, 3, 257-260.	1.0	1
115	Linkage Analysis of Chromosome 1q Markers in 136 Prostate Cancer Families. American Journal of Human Genetics, 1998, 62, 653-658.	2.6	123

#	Article	IF	CITATIONS
116	Evidence for Autosomal Dominant Inheritance of Prostate Cancer. American Journal of Human Genetics, 1998, 62, 1425-1438.	2.6	198
117	BIOLOGICAL AGGRESSIVENESS OF HEREDITARY PROSTATE CANCER: LONG-TERM EVALUATION FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 1998, 160, 660-663.	0.2	69
118	Predisposing Gene for Early-Onset Prostate Cancer, Localized on Chromosome 1q42.2-43. American Journal of Human Genetics, 1998, 62, 1416-1424.	2.6	327
119	Significance of Familial History of Prostate Cancer to Traditional Prognostic Variables, Genetic Biomarkers, and Recurrence after Radical Prostatectomy. Urology, 1998, 51, 970-976.	0.5	59
120	Familial study of prostate cancer in Jamaica. Urology, 1998, 52, 441-443.	0.5	43
122	Screening for Prostate Cancer - More Questions than Answers. Acta Oncológica, 1998, 37, 515-532.	0.8	9
123	The Concise Handbook of Family Cancer Syndromes. Journal of the National Cancer Institute, 1998, 90, 1039-1071.	3.0	303
124	Hereditary Prostate Cancer and Other Genetic Predispositions to Prostate Cancer. Urologia Internationalis, 1998, 60, 30-34.	0.6	30
125	Risk of Uterine Leiomyomata among Premenopausal Women in Relation to Body Size and Cigarette Smoking. Epidemiology, 1998, 9, 511-517.	1.2	122
126	Significance of Measurement of Prostate Specific Antigen (PSA) in Familial Prostate Cancer Lines Tohoku Journal of Experimental Medicine, 1998, 184, 21-28.	0.5	4
128	Confirmation of Prostate Cancer Susceptibility Genes Using High-Risk Families. Journal of the National Cancer Institute Monographs, 1999, 1999, 81-87.	0.9	9
129	A Case-Cohort Study on Prostate Cancer Risk in Relation to Family History of Prostate Cancer. Epidemiology, 1999, 10, 192-195.	1.2	24
130	Prostate Cancer Susceptibility Locus HPC1 in Utah High-Risk Pedigrees. Human Molecular Genetics, 1999, 8, 2437-2442.	1.4	67
131	Hereditary Prostate Cancer. Scandinavian Journal of Urology and Nephrology, 1999, 33, 25-28.	1.4	11
132	Dietary Fat and Prostate Cancer: Current Status. Journal of the National Cancer Institute, 1999, 91, 414-428.	3.0	217
133	Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis, 1999, 20, 1727-1731.	1.3	175
134	Molecular biology of prostate carcinogenesis. Critical Reviews in Oncology/Hematology, 1999, 32, 197-208.	2.0	22
136	Familial prostate cancer: outcome following radiation therapy with or without adjuvant androgen ablation. International Journal of Radiation Oncology Biology Physics, 1999, 43, 379-383.	0.4	23

#	Article	IF	CITATIONS
137	Genetic predisposition to prostate cancer. Prostate Cancer and Prostatic Diseases, 1999, 2, 9-15.	2.0	57
138	Risk factors for prostate cancer: results from the Canadian National Enhanced Cancer Surveillance System. The Canadian Cancer Registries Epidemiology Research Group. Cancer Causes and Control, 1999, 10, 355-367.	0.8	168
141	Genetic epidemiology of prostate cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 1999, 1423, F1-F13.	3.3	18
142	Prostate Cancer Susceptibility Genes: A Current Update. Prostate Journal, 1999, 1, 115-119.	0.2	0
143	Adherence by African American men to prostate cancer education and early detection., 1999, 86, 88-104.		82
144	Age specific risks of familial prostate carcinoma. Cancer, 1999, 86, 477-483.	2.0	43
145	Links between genetic and environmental factors and prostate cancer risk., 1999, 39, 262-268.		39
146	Prevention of prostate-related cancers in Lobund-Wistar rats. , 1999, 39, 305-309.		27
147	Genetic and Environmental Factors in Prostate Cancer Genesis:Identifying High-Risk Cohorts. European Urology, 1999, 35, 362-369.	0.9	64
148	Evidence for a Rare Prostate Cancer–Susceptibility Locus at Chromosome 1p36. American Journal of Human Genetics, 1999, 64, 776-787.	2.6	292
149	Analysis of Chromosome 1q42.2-43 in 152 Families with High Risk of Prostate Cancer. American Journal of Human Genetics, 1999, 64, 1087-1095.	2.6	70
150	In Swedish Families with Hereditary Prostate Cancer, Linkage to the HPC1 Locus on Chromosome 1q24-25 Is Restricted to Families with Early-Onset Prostate Cancer. American Journal of Human Genetics, 1999, 65, 134-140.	2.6	73
151	The Jewish Ashkenazi Founder Mutations in the BRCA1/BRCA2 Genes Are Not Found at an Increased Frequency in Ashkenazi Patients with Prostate Cancer. American Journal of Human Genetics, 1999, 65, 921-924.	2.6	63
152	Familial and hereditary prostate cancer in southern Sweden. A population-based case–control study. European Journal of Cancer, 1999, 35, 272-277.	1.3	71
153	SCREENING FOR CANCER IN THE PATIENT WITH RHEUMATIC DISEASE. Rheumatic Disease Clinics of North America, 1999, 25, 719-744.	0.8	5
154	Knowledge, attitudes, and screening practices among older men regarding prostate cancer. American Journal of Public Health, 2000, 90, 1595-1600.	1.5	138
155	Diagnosis of localized prostate cancer: 10 years of progress. Current Opinion in Urology, 2000, 10, 319-327.	0.9	12
156	Bias Associated with Study Protocols in Epidemiologic Studies of Disease Familial Aggregation. American Journal of Epidemiology, 2000, 151, 927-937.	1.6	30

#	Article	IF	CITATIONS
157	Racial differences in prostate cancer growth: Apoptosis and cell proliferation in Caucasian and African-American patients., 2000, 42, 130-136.		37
158	Linkage analysis of 150 high-risk prostate cancer families at 1q24-25., 2000, 18, 251-275.		43
159	Low frequency of allelic imbalance at the prostate cancer susceptibility lociHPC1 and 1p36 in Swedish men with hereditary prostate cancer. Genes Chromosomes and Cancer, 2000, 29, 292-296.	1.5	16
160	Apolipoprotein E genotype is not linked to locally recurrent hormone-refractory prostate cancer. Prostate Cancer and Prostatic Diseases, 2000, 3, 107-109.	2.0	6
161	High risk genes predisposing to prostate cancer developmentâ€"do they exist?. Prostate Cancer and Prostatic Diseases, 2000, 3, 241-247.	2.0	20
162	No evidence of linkage to chromosome 1q42.2–43 in 131 prostate cancer families from the ACTANE Consortium. British Journal of Cancer, 2000, 83, 1654-1658.	2.9	7
163	New insights and candidate genes and their implications for care of patients with hereditary prostate cancer. Current Urology Reports, 2000, 1, 9-14.	1.0	1
164	An Allele-Specific Polymerase Chain Reaction Method for the Determination of the D85Y Polymorphism in the Human UDPGlucuronosyltransferase 2B15 Gene in a Case-Control Study of Prostate Cancer. Annals of Surgical Oncology, 2000, 7, 777-782.	0.7	78
165	Genetic Susceptibility to Prostate Cancer. European Urology, 2000, 38, 121-130.	0.9	3
166	Chapter 2: The Role of Steroid Hormones in Prostate Carcinogenesis. Journal of the National Cancer Institute Monographs, 2000, 2000, 39-66.	0.9	270
167	Prostate Cancer Screening Trends of New York State Men at Least 50 Years of Age, 1994 to 1997. Preventive Medicine, 2000, 31, 195-202.	1.6	25
168	Linkage Analyses at the Chromosome 1 Loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in Families with Hereditary Prostate Cancer. American Journal of Human Genetics, 2000, 66, 539-546.	2.6	91
169	A Genome Screen of Multiplex Sibships with Prostate Cancer. American Journal of Human Genetics, 2000, 66, 933-944.	2.6	147
170	A Genomic Scan of Families with Prostate Cancer Identifies Multiple Regions of Interest. American Journal of Human Genetics, 2000, 67, 100-109.	2.6	88
171	Evidence for a Prostate Cancer–Susceptibility Locus on Chromosome 20. American Journal of Human Genetics, 2000, 67, 82-91.	2.6	213
172	Genetics of Prostate Cancer: Too Many Loci, Too Few Genes. American Journal of Human Genetics, 2000, 67, 1367-1375.	2.6	170
173	Cellular and Molecular Pathology of Prostate Cancer Precursors. Scandinavian Journal of Urology and Nephrology, 2000, 34, 19-43.	1.4	63
174	CANCER SCREENING IN THE ELDERLY POPULATION. Hematology/Oncology Clinics of North America, 2000, 14, 89-112.	0.9	14

#	Article	IF	Citations
175	EAU Guidelines on Prostate Cancer. European Urology, 2001, 40, 97-101.	0.9	92
176	Psychosocial and educational intervention trials in prostate cancer. Seminars in Oncology Nursing, 2001, 17, 129-137.	0.7	17
177	Analysis of the Prostate Cancer–Susceptibility Locus HPC20 in 172 Families Affected by Prostate Cancer. American Journal of Human Genetics, 2001, 68, 795-801.	2.6	51
178	Segregation Analyses of 1,476 Population-Based Australian Families Affected by Prostate Cancer. American Journal of Human Genetics, 2001, 68, 1207-1218.	2.6	84
179	A Genome Screen of Families with Multiple Cases of Prostate Cancer: Evidence of Genetic Heterogeneity. American Journal of Human Genetics, 2001, 69, 148-158.	2.6	80
180	Diet and the duration of testosterone-dependent prostate cancer in Lobund–Wistar rats. Cancer Letters, 2001, 173, 127-131.	3.2	21
181	African American men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials. Urology, 2001, 57, 178-181.	0.5	40
182	Prostate-specific antigen best practice policyâ€"part I: early detection and diagnosis of prostate cancer. Urology, 2001, 57, 217-224.	0.5	81
183	EPIDEMIOLOGY OF PROSTATIC CANCER IN EAST ASIA. Archives of Andrology, 2001, 47, 195-201.	1.0	12
184	Molecular genetics of prostate cancer. Annals of Medicine, 2001, 33, 130-141.	1.5	82
185	The Role of Family History in Personal Prevention Practices among US Women Physicians. Public Health Genomics, 2001, 4, 102-108.	1.0	2
186	Genetic Linkage Analysis of Prostate Cancer Families to Xq27–28. Human Heredity, 2001, 51, 107-113.	0.4	46
187	Familial Aggregation of Prostate Cancer Management while Waiting for the Identification of Hereditary Prostate Cancer Genes. European Urology, 2001, 39, 19-21.	0.9	2
188	A population-based study of clinical and pathological prognostic characteristics of men with familial and. BJU International, 2001, 84, 311-315.	1.3	18
189	Hereditary prostate cancer. BJU International, 2001, 85, 588-598.	1.3	39
190	Low frequency of microsatellite instability in hereditary prostate cancer. BJU International, 2001, 87, 334-338.	1.3	14
191	Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate, 2001, 49, 263-266.	1.2	69
192	Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. International Journal of Cancer, 2001, 95, 354-359.	2.3	48

#	Article	IF	CITATIONS
193	Prostate cancer susceptibility genes: many studies, many results, no answers. Cancer and Metastasis Reviews, 2001, 20, 155-164.	2.7	26
194	Psychological and screening profiles of first-degree relatives of prostate cancer patients. Journal of Behavioral Medicine, 2001, 24, 247-258.	1.1	39
195	Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: a population-based, cancer registry study in Finland. Cancer Causes and Control, 2001, 12, 223-230.	0.8	42
196	PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. European Journal of Human Genetics, 2001, 9, 135-142.	1.4	58
197	Familial Prostate Cancer. Epidemiologic Reviews, 2001, 23, 19-23.	1.3	104
198	Smoking and Prostate Cancer. Epidemiologic Reviews, 2001, 23, 115-125.	1.3	114
199	Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Human Molecular Genetics, 2001, 10, 2313-2318.	1.4	101
200	20 Immunohistochemical expression of raf kinase inhibitor protein in prostate carcinoma. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2002, , 471-479.	0.0	0
201	Molecular Characterization of Canine Prostaglandin G/H Synthase-2 and Regulation in Prostatic Adenocarcinoma Cells in Vitro. Endocrinology, 2002, 143, 1134-1143.	1.4	15
202	Polymorphisms of GSTP1 and related genes and prostate cancer risk. Prostate Cancer and Prostatic Diseases, 2002, 5, 22-27.	2.0	42
203	Androgen Receptor CAG Repeats and Prostate Cancer. American Journal of Epidemiology, 2002, 155, 883-890.	1.6	109
205	Can family history be used as a tool for public health and preventive medicine?. Genetics in Medicine, 2002, 4, 304-310.	1.1	314
206	Perspective: Prostate Cancer Susceptibility Genes. Endocrinology, 2002, 143, 2029-2040.	1.4	49
207	Analysis of the RNASEL Gene in Familial and Sporadic Prostate Cancer. American Journal of Human Genetics, 2002, 71, 116-123.	2.6	105
208	A Review of Genetic Polymorphisms and Prostate Cancer Risk. Annals of Epidemiology, 2002, 12, 182-196.	0.9	92
209	Germline Mutations in the Ribonuclease L Gene in Families Showing Linkage With HPC1. Journal of Urology, 2002, 168, 372-372.	0.2	0
210	Screening for Prostate Cancer in High Risk Populations. Journal of Urology, 2002, 168, 1980-1984.	0.2	79
211	Prostate cancer susceptibility genes: Many studies, many results, no answers. , 2002, , 19-28.		0

#	Article	IF	CITATIONS
212	The diet, prostate inflammation, and the development of prostate cancer., 2002,, 227-240.		0
215	Two pedigrees of hereditary prostate cancer. International Journal of Clinical Oncology, 2002, 7, 187-191.	1.0	0
216	Psychological benefits of prostate cancer screening: the role of reassurance. Health Expectations, 2002, 5, 104-113.	1.1	52
217	Role of family history and ethnicity on the mode and age of prostate cancer presentation. Prostate, 2002, 50, 216-221.	1.2	47
218	Confirmation of the prostate cancer susceptibility locus HPCX in a set of 104 German prostate cancer families. Prostate, 2002, 52, 12-19.	1.2	32
219	Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nature Genetics, 2002, 30, 181-184.	9.4	470
220	Segregation analysis of prostate cancer in 1,719 white, African-American and Asian-American families in the United States and Canada. Cancer Causes and Control, 2002, 13, 471-482.	0.8	53
221	The diet, prostate inflammation, and the development of prostate cancer. Cancer and Metastasis Reviews, 2002, 21, 3-16.	2.7	116
222	Risk of prostate cancer associated with a family history in an era of rapid increase in prostate cancer diagnosis (Australia). Cancer Causes and Control, 2003, 14, 161-166.	0.8	22
223	Spouse controls in family case-control studies: a methodological consideration. Familial Cancer, 2003, 2, 101-108.	0.9	11
224	Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma. Cancer, 2003, 97, 1894-1903.	2.0	169
225	A neurocomputational model for prostate carcinoma detection. Cancer, 2003, 98, 1849-1854.	2.0	37
226	Current status of the molecular genetics of human prostatic adenocarcinomas. International Journal of Cancer, 2003, 103, 285-293.	2.3	67
227	Oligogenic segregation analysis of hereditary prostate cancer pedigrees: Evidence for multiple loci affecting age at onset. International Journal of Cancer, 2003, 105, 630-635.	2.3	34
228	Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-analysis. International Journal of Cancer, 2003, 107, 797-803.	2.3	139
229	Genetic counseling for prostate cancer risk. Clinical Genetics, 2003, 63, 169-176.	1.0	16
230	A systematic review and meta-analysis of familial prostate cancer risk. BJU International, 2003, 91, 789-794.	1.3	219
231	Segregation Analysis of Prostate Cancer in France: Evidence for Autosomal Dominant Inheritance and Residual Brother-brother Dependence. Annals of Human Genetics, 2003, 67, 125-137.	0.3	36

#	Article	IF	CITATIONS
232	Familial aggregation of prostate cancer in African-Americans and white Americans. Prostate, 2003, 56, 256-262.	1.2	25
233	Genomic scan of 254 hereditary prostate cancer families. Prostate, 2003, 57, 309-319.	1.2	59
234	Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 nearBRCA1. Prostate, 2003, 57, 326-334.	1.2	90
235	Genome linkage screen for prostate cancer susceptibility loci: Results from the Mayo Clinic familial prostate cancer study. Prostate, 2003, 57, 335-346.	1.2	48
236	Cáncer de próstata. Medicine, 2003, 8, 6159-6168.	0.0	0
237	Second Primary Cancers in Men With Prostate Cancer: An Increased Risk of Male Breast Cancer. Journal of Urology, 2003, 169, 1345-1348.	0.2	82
238	Implications for RNase L in Prostate Cancer Biology. Biochemistry, 2003, 42, 1805-1812.	1.2	147
239	Population Screening for Prostate Cancer and Emerging Concepts for Young Men. Clinical Prostate Cancer, 2003, 2, 87-97.	2.1	27
240	Prostate Development and Carcinogenesis. International Review of Cytology, 2003, 227, 65-130.	6.2	24
241	Epidemiology of prostate cancer. Urology, 2003, 62, 3-12.	0.5	421
242	Krýppel Cripples Prostate Cancer. American Journal of Pathology, 2003, 162, 1047-1052.	1.9	41
243	Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology, 2003, 62, 86-91.	0.5	117
244	Molecular Pathways to Prostate Cancer. Journal of Urology, 2003, 170, 2444-2452.	0.2	119
245	Prostate Cancer. New England Journal of Medicine, 2003, 349, 366-381.	13.9	970
246	Confirmation of Linkage of Prostate Cancer Aggressiveness with Chromosome 19q. American Journal of Human Genetics, 2003, 72, 759-762.	2.6	70
247	New Paraoxonase 1 Polymorphism I102V and the Risk of Prostate Cancer in Finnish Men. Journal of the National Cancer Institute, 2003, 95, 812-818.	3.0	62
248	Prostate cancer susceptibility genes: lessons learned and challenges posed Endocrine-Related Cancer, 2003, 10, 225-259.	1.6	81
249	Cancer Survival in Kentucky and Health Insurance Coverage. Archives of Internal Medicine, 2003, 163, 2135.	4.3	135

#	Article	IF	CITATIONS
250	Mutational Profiling in the Human Genome. Cold Spring Harbor Symposia on Quantitative Biology, 2003, 68, 23-30.	2.0	7
251	Improving quality of life in men with prostate cancer: A randomized controlled trial of group education interventions Health Psychology, 2003, 22, 443-452.	1.3	242
253	Hereditary Prostate Cancer., 2003,, 145-158.		0
256	The complex genetic epidemiology of prostate cancer. Human Molecular Genetics, 2004, 13, 103R-121.	1.4	298
257	Changing trends of prostate cancer in Asia. Aging Male, 2004, 7, 120-132.	0.9	101
258	NBS1 Is a Prostate Cancer Susceptibility Gene. Cancer Research, 2004, 64, 1215-1219.	0.4	141
259	Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. Journal of Medical Genetics, 2004, 41, 81-91.	1.5	148
260	The global state of prostate cancer: epidemiology and screening in the second millennium. BJU International, 2004, 94, 1-2.	1.3	39
261	Genomewide linkage analysis of familial prostate cancer in the Japanese population. Journal of Human Genetics, 2004, 49, 9-15.	1.1	40
262	Genetic alterations in prostate cancer. Current Prostate Reports, 2004, 2, 51-59.	0.1	0
263	Genetic alterations in prostate cancer. Current Urology Reports, 2004, 5, 157-165.	1.0	5
264	Association of prostate cancer risk and aggressiveness to androgen pathway genes:SRD5A2,CYP17, and theAR. Prostate, 2004, 59, 69-76.	1.2	76
265	Analysis of the macrophage scavenger receptor 1 gene in Swedish hereditary and sporadic prostate cancer. Prostate, 2004, 59, 132-140.	1.2	24
266	Prostate cancer and polymorphism D85Y in gene for dihydrotestosterone degrading enzyme UGT2B15: Frequency of DD homozygotes increases with Gleason Score. Prostate, 2004, 59, 436-439.	1.2	41
267	Unravelling the genetics of prostate cancer. American Journal of Medical Genetics Part A, 2004, 129C, 65-73.	2.4	56
268	Risk perception and concern among brothers of men with prostate carcinoma. Cancer, 2004, 100, 1537-1544.	2.0	34
269	Human prostate cancer risk factors. Cancer, 2004, 101, 2371-2490.	2.0	500
270	Synthesis and biological evaluation of novel cytotoxic phospholipids for prostate cancer. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4919-4923.	1.0	17

#	Article	IF	Citations
271	Preventive Health Care in the Elderly Population: A Guide for Practicing Physicians. Mayo Clinic Proceedings, 2004, 79, 416-427.	1.4	9
273	Management of Prostate Cancer., 2004, , .		2
274	Time trends in pathologic features of radical prostatectomyâ€"impact of family history. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 169-173.	0.8	7
275	Relationship of body mass index and prostate specific antigen in a population-based studyâ <sup>*</sup> †. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 127-131.	0.8	23
276	Underutilization of Digital Rectal Examination When Screening for Prostate Cancer. Archives of Internal Medicine, 2004, 164, 313.	4.3	20
277	Metastasis suppressor genes: a role for raf kinase inhibitor protein (RKIP). Anti-Cancer Drugs, 2004, 15, 663-669.	0.7	55
278	occupational activity and risk of prostate cancer in ireland. Journal of Radiotherapy in Practice, 2004, 4, 102-106.	0.2	7
279	The Clinical Genetics of Prostate Cancer. Hereditary Cancer in Clinical Practice, 2004, 2, 111.	0.6	5
281	Prostate Cancer Screening in Australasia. Clinical Oncology, 2005, 17, 231-233.	0.6	5
282	Familial and Hereditary Prostate Cancer by Definition in an Italian Surgical Series: Clinical Features and Outcome. European Urology, 2005, 47, 761-768.	0.9	28
283	Molecular changes in prostatic cancer. Surgical Oncology, 2005, 14, 91-104.	0.8	10
284	Association of prostate cancer family history with histopathological and clinical characteristics of prostate tumors. International Journal of Cancer, 2005, 113, 471-474.	2.3	17
285	A discussion of general prostate cancer screening versus targeted diagnosis in younger men. Current Prostate Reports, 2005, 3, 99-111.	0.1	0
286	Prostate Cancer in the Elderly. International Urology and Nephrology, 2005, 37, 797-806.	0.6	7
287	Population-based risk assessment for other cancers in relatives of hereditary prostate cancer (HPC) cases. Prostate, 2005, 64, 347-355.	1.2	24
288	Screening for Prostate Cancer in Military Populations. Military Medicine, 2005, 170, 905-914.	0.4	8
290	Approach to common chronic disorders of adulthood. , 2005, , .		0
291	Hereditary Predisposition and Prostate Cancer. Urologia, 2005, 72, 205-214.	0.3	0

#	Article	IF	CITATIONS
292	Patients with a Family History of Cancer: Identification and Management. Journal of the American Board of Family Medicine, 2005, 18, 211-217.	0.8	27
293	Prostate Cancer and the Gay Male. Journal of Gay and Lesbian Psychotherapy, 2005, 9, 9-27.	0.4	17
294	Risk of prostate cancer and family history of cancer: a population-based study in China. Prostate Cancer and Prostatic Diseases, 2005, 8, 60-65.	2.0	9
295	Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer and Prostatic Diseases, 2005, 8, 95-102.	2.0	49
297	Adenocarcinoma of the Prostate: Epidemiological Trends, Screening, Diagnosis, and Surgical Management of Localized Disease. Mayo Clinic Proceedings, 2005, 80, 899-907.	1.4	58
298	Association between family history of prostate and breast cancer among African-American men with prostate cancer. Urology, 2006, 68, 1072-1076.	0.5	13
299	Single nucleotide polymorphisms: Early diagnosis and risk assessment in genitourinary malignancy. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 224-230.	0.8	0
302	The Role of Prevalence in the Diagnosis of Prostate Cancer. Cancer Control, 2006, 13, 158-168.	0.7	73
303	Catechol-O-methyltransferase Gene Polymorphisms in Benign Prostatic Hyperplasia and Sporadic Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 238-244.	1.1	31
304	Genetic Susceptibility to Prostate Cancer: Prostate-specific Antigen and its Interaction with the Androgen Receptor (United States). Cancer Causes and Control, 2006, 17, 187-197.	0.8	28
305	Genome-wide linkage scan for prostate cancer susceptibility genes in men with aggressive disease: significant evidence for linkage at chromosome 15q12. Human Genetics, 2006, 119, 400-407.	1.8	21
306	Mitogen-Activated Protein Kinase Signaling is Activated in Prostate Tumors but not Mediated by B-RAF Mutations. European Urology, 2006, 50, 1102-1110.	0.9	20
307	Genetic Susceptibility to Aggressive Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1761-1764.	1.1	18
308	Phorate Exposure and Incidence of Cancer in the Agricultural Health Study. Environmental Health Perspectives, 2006, 114, 1205-1209.	2.8	95
310	Sequence Variants of Estrogen Receptor $\hat{l}^2$ and Risk of Prostate Cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1973-1981.	1.1	33
311	Reducing Prostate Cancer Morbidity and Mortality in African American Men: Issues and Challenges. Clinical Journal of Oncology Nursing, 2007, 11, 865-872.	0.3	25
312	Ghrelin and Prostate Cancer. Vitamins and Hormones, 2007, 77, 301-324.	0.7	24
313	Confirmation of a Positive Association between Prostate Cancer Risk and a Locus at Chromosome 8q24. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 809-814.	1.1	88

#	Article	IF	CITATIONS
314	Short report. The AIDIT and IMPACT conference 2006: Outcomes and future directions. Hereditary Cancer in Clinical Practice, 2007, 5, 53.	0.6	1
315	Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin. Hereditary Cancer in Clinical Practice, 2007, 5, 164.	0.6	7
316	Prostate cancer ? presentation, diagnosis and treatment: what does the literature say?. International Journal of Urological Nursing, 2007, $1$ , 6-17.	0.1	5
317	Family history of cancer and utilization of prostate, colorectal and skin cancer screening tests in U.S. men. Preventive Medicine, 2007, 44, 459-464.	1.6	27
318	Genetic etiology of hereditary prostate cancer. Frontiers in Bioscience - Landmark, 2007, 12, 4101.	3.0	48
319	Epithelial Tumors. , 2007, , 441-524.		0
320	Lack of Effect of Walnuts on Serum Levels of Prostate Specific Antigen: A Brief Report. Journal of the American College of Nutrition, 2007, 26, 317-320.	1.1	14
321	Higher Frequency of Familial Clustering of Prostate Cancer in French-Canadian Men. Journal of Urology, 2007, 178, 1265-1270.	0.2	1
323	Genome-wide linkage analysis for aggressive prostate cancer in Utah high-risk pedigrees. Prostate, 2007, 67, 605-613.	1.2	22
324	Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nature Genetics, 2007, 39, 645-649.	9.4	1,059
325	Increased cancer risk for individuals with a family history of prostate cancer, colorectal cancer, and melanoma and their associated screening recommendations and practices. Cancer Causes and Control, 2008, 19, 1-12.	0.8	24
326	Metabolic syndrome in sub-Saharan Africa: "smaller twin―of a region's prostatic diseases?. International Urology and Nephrology, 2008, 40, 909-920.	0.6	17
327	Analysis of the gene coding for the BRCA2â€Interacting protein PALB2 in hereditary prostate cancer. Prostate, 2008, 68, 675-678.	1.2	36
328	Evaluation of a variant in the transcription factor 7â€like 2 ( <i>TCF7L2</i> ) gene and prostate cancer risk in a populationâ€based study. Prostate, 2008, 68, 740-747.	1.2	32
329	Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. Prostate, 2008, 68, 1582-1591.	1.2	57
330	Association of HPC2/ELAC2 and RNASEL nonâ€synonymous variants with prostate cancer risk in African American familial and sporadic cases. Prostate, 2008, 68, 1790-1797.	1.2	33
331	Multiple loci identified in a genome-wide association study of prostate cancer. Nature Genetics, 2008, 40, 310-315.	9.4	871
332	Evidenceâ€based Clinical Practice Guidelines for Prostate Cancer (Summary – JUA 2006 Edition). International Journal of Urology, 2008, 15, 1-18.	0.5	17

#	Article	IF	CITATIONS
333	Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Letters, 2008, 270, 173-180.	3.2	19
334	Prostate cancer. Lancet, The, 2008, 371, 1710-1721.	6.3	421
335	Prostate Cancer Susceptibility Loci: Finding the Genes. Advances in Experimental Medicine and Biology, 2008, 617, 179-190.	0.8	15
336	Psychosocial Factors Associated with an Increased Frequency of Prostate Cancer Screening in Men Ages 40 to 79 Years: The Olmsted County Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3588-3592.	1.1	38
337	Urological Oncology., 2008,,.		3
338	Update on Prostate-Specific Antigen Testing for the Early Detection of Prostate Cancer. Laboratory Medicine, 2008, 39, 613-621.	0.8	2
339	Recruitment strategies and comparison of prostate cancer-specific clinical data on African-American and Caucasian males with and without family history. Prostate Cancer and Prostatic Diseases, 2008, 11, 274-279.	2.0	5
340	Effect of Genetic Variability within 8q24 on Aggressiveness Patterns at Diagnosis and Familial Status of Prostate Cancer. Clinical Cancer Research, 2008, 14, 5635-5639.	3.2	30
341	Two-Graph Receiver Operating Characteristic Analysis to Assess Prostate-Specific Antigen as a Predictive Factor for Metastatic Prostate Cancer. Laboratory Medicine, 2008, 39, 93-96.	0.8	0
342	Predictors of Prostate Cancer Screening among Older Immigrant Men. Journal of the National Medical Association, 2008, 100, 1168-1174.	0.6	8
343	Altered insulin sensitivity, insulin secretion and lipid profile in non-diabetic prostate carcinoma. Acta Physiologica Hungarica, 2008, 95, 97-105.	0.9	12
344	Germ-Line Mutations in Mismatch Repair Genes Associated with Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2460-2467.	1.1	103
345	Interest in genetic testing among affected men from hereditary prostate cancer families and their unaffected male relatives. Genetics in Medicine, 2009, 11, 344-355.	1.1	6
346	Polymorphism L26V in the Cathepsin B Gene may be Associated with a Risk of Prostate Cancer and Differentiation. Journal of International Medical Research, 2009, 37, 1604-1610.	0.4	6
347	Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2009, 10, 241-246.	1.0	22
348	Undetectable Prostate-Specific Antigen in the Absence of Previous Prostatectomy: Laboratory Error or True Finding?. Laboratory Medicine, 2009, 40, 466-469.	0.8	0
349	Analysis of Recently Identified Prostate Cancer Susceptibility Loci in a Population-based Study: Associations with Family History and Clinical Features. Clinical Cancer Research, 2009, 15, 3231-3237.	3.2	62
350	Concordant colon tumors in monozygotic twins previously treated for prostate cancer. Familial Cancer, 2009, 8, 167-171.	0.9	5

#	Article	IF	CITATIONS
351	Insulin: a novel agent in the pathogenesis of prostate cancer. International Urology and Nephrology, 2009, 41, 267-272.	0.6	43
352	Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners. BMC Family Practice, 2009, 10, 3.	2.9	37
353	Molecular markers in prostate cancer. Part I: predicting lethality. Asian Journal of Andrology, 2009, 11, 14-21.	0.8	7
354	Effect of Family History on Outcomes in Patients Treated With Definitive Brachytherapy for Clinically Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 73, 24-29.	0.4	9
356	Genetics of Prostate Cancer Risk. Mount Sinai Journal of Medicine, 2010, 77, 643-654.	1.9	22
357	Association between family history of cancers and risk of prostate cancer. Journal of Men's Health, 2010, 7, 45-54.	0.1	4
358	Markers for Detection of Prostate Cancers, 2010, 2, 1125-1154.	1.7	39
360	Single and Multivariate Associations of <i>MSR1, ELAC2</i> , and <i>RNASEL</i> with Prostate Cancer in an Ethnic Diverse Cohort of Men. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 588-599.	1.1	44
361	Deletions of the Androgen-Metabolizing <i>UGT2B </i> Senes Have an Effect on Circulating Steroid Levels and Biochemical Recurrence after Radical Prostatectomy in Localized Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1550-E1557.	1.8	54
362	Screening for Prostate Cancer. New England Journal of Medicine, 2011, 365, 2013-2019.	13.9	183
363	EphB2 SNPs and Sporadic Prostate Cancer Risk in African American Men. PLoS ONE, 2011, 6, e19494.	1.1	21
364	An Epidemiological Reappraisal of the Familial Aggregation of Prostate Cancer: A Meta-Analysis. PLoS ONE, 2011, 6, e27130.	1.1	126
365	SRD5A Polymorphisms and Biochemical Failure After Radical Prostatectomy. European Urology, 2011, 60, 1226-1234.	0.9	41
366	A review of African American-white differences in risk factors for cancer: prostate cancer. Cancer Causes and Control, 2011, 22, 341-357.	0.8	41
368	An update analysis of two polymorphisms in encoding ribonuclease L gene and prostate cancer risk: involving 13,372 cases and 11,953 controls. Genes and Nutrition, 2011, 6, 397-402.	1.2	5
369	Metaâ€analysis of genomeâ€wide and replication association studies on prostate cancer. Prostate, 2011, 71, 209-224.	1.2	50
370	Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers. Cancer Epidemiology, 2011, 35, e18-e24.	0.8	12
371	The Genetics of Cancer Risk. Cancer Journal (Sudbury, Mass), 2011, 17, 416-422.	1.0	50

#	Article	IF	CITATIONS
372	Gallic acid suppresses the migration and invasion of PC-3 human prostate cancer cells via inhibition of matrix metalloproteinase-2 and -9 signaling pathways. Oncology Reports, 2011, 26, 177-84.	1.2	78
373	High-Intensity Focused Ultrasound for Prostate Cancer: Long-Term Followup and Complications Rate. Advances in Urology, 2012, 2012, 1-4.	0.6	16
374	1929 ASSOCIATION BETWEEN FAMILY HISTORY OF PROSTATE CANCER AND POSITIVE BIOPSIES IN A BRAZILIAN SCREENING PROGRAM. Journal of Urology, 2012, 187, .	0.2	0
375	Effect of family history on outcome in German patients treated with radical prostatectomy for clinically localised prostate cancer. European Journal of Cancer, 2012, 48, 1312-1317.	1.3	11
376	Increased risk of lung cancer in individuals with a family history of the disease: A pooled analysis from the International Lung Cancer Consortium. European Journal of Cancer, 2012, 48, 1957-1968.	1.3	143
377	Emergent trends in the reported incidence of prostate cancer in Nigeria. Clinical Epidemiology, 2012, 4, 19.	1.5	14
378	Review on proteomic analyses of benzo[a]pyrene toxicity. Proteomics, 2012, 12, 1731-1755.	1.3	96
379	Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). Journal of Internal Medicine, 2012, 272, 85-92.	2.7	27
380	Urgent parathyroidectomy. ANZ Journal of Surgery, 2012, 82, 193-194.	0.3	0
381	Life insurance and genetic testing for prostate cancer: what advice for patients?. ANZ Journal of Surgery, 2012, 82, 194-196.	0.3	2
382	Mastering the totally extraperitoneal technique is a prerequisite for successful inguinal hernia repair. ANZ Journal of Surgery, 2012, 82, 196-197.	0.3	3
383	Family History of Prostate Cancer in a Black Population. Journal of Immigrant and Minority Health, 2013, 15, 1107-1112.	0.8	11
384	Genetic heterogeneity in Finnish hereditary prostate cancer using ordered subset analysis. European Journal of Human Genetics, 2013, 21, 437-443.	1.4	4
385	Cancer of the Kidney and Urogenital Tract. , 2013, , 1-17.		0
386	The Association Between the Disclosure and the Realization of Information Security Risk Factors. Information Systems Research, 2013, 24, 201-218.	2.2	139
387	Family History and Health Risk Assessment. , 2013, , 306-323.		1
388	Actualización en cáncer de próstata. Medicine, 2013, 11, 1578-1587.	0.0	1
389	Association between family history of prostate cancer and positive biopsies in a Brazilian screening program. World Journal of Urology, 2013, 31, 1273-1278.	1.2	4

#	Article	IF	CITATIONS
390	Prostate Cancer Genetics., 2013, , 135-146.		0
391	Genetics and genomics of prostate cancer. Asian Journal of Andrology, 2013, 15, 309-313.	0.8	22
392	Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. European Journal of Cancer, 2013, 49, 938-945.	1.3	65
393	Prostate cancer in Denmark 1978–2009 — trends in incidence and mortality. Acta Oncológica, 2013, 52, 831-836.	0.8	36
394	Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC). Journal of Cancer, 2013, 4, 304-314.	1.2	26
395	Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue. European Journal of Histochemistry, 2013, 57, 13.	0.6	46
396	Molecular Pathways in Prostate Cancer. Nephro-Urology Monthly, 2013, 5, 792-800.	0.0	56
397	Prostate Cancer Disparities throughout the Cancer Control Continuum. Social Sciences, 2013, 2, 247-269.	0.7	5
398	Cerebellar Degeneration-Related Autoantigen 1 (CDR1) Gene Expression in Prostate Cancer Cell Lines. International Journal of Biological Markers, 2014, 29, 288-290.	0.7	5
399	Synthesis and Cytotoxic Activity Evaluation of Novel Arylpiperazine Derivatives on Human Prostate Cancer Cell Lines. Molecules, 2014, 19, 12048-12064.	1.7	20
401	Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. British Journal of Cancer, 2014, 111, 1421-1431.	2.9	26
402	The clinic-pathological characteristics of prostate cancer in an Irish subpopulation with a serum PSA less than 4.0ng/ml. Journal of Clinical Urology, 2014, 7, 338-343.	0.1	0
403	PARP-1 and CASP3 genes are up-regulated in LNCaP and PC-3 prostate cancer cell lines. Human Cell, 2014, 27, 172-175.	1.2	4
404	A Practical Guide to Human Cancer Genetics. , 2014, , .		8
406	Application of the 2013 American Urological Association early detection of prostate cancer guideline: Who will we miss?. World Journal of Urology, 2014, 32, 959-964.	1.2	13
407	The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: Which markers matter and how should they be used?. World Journal of Urology, 2014, 32, 871-880.	1.2	8
408	Metabolism of Human Diseases. , 2014, , .		4
409	Complicaciones infecciosas de la biopsia transrectal de próstata con preparación intestinal a base de levofloxacino y aceite mineral. Revista Mexicana De Urologia, 2015, 75, 198-201.	0.0	0

#	Article	IF	CITATIONS
410	Functional and Structural Consequences of Damaging Single Nucleotide Polymorphisms in Human Prostate Cancer Predisposition Gene RNASEL. BioMed Research International, 2015, 2015, 1-15.	0.9	14
411	Efectividad de los micronutrientes en la prevenci $\tilde{A}^3$ n del c $\tilde{A}_1$ ncer de pr $\tilde{A}^3$ stata Revista Facultad De Medicina, 2015, 62, 65-72.	0.0	1
412	Computer-Aided Detection and diagnosis for prostate cancer based on mono and multi-parametric MRI: A review. Computers in Biology and Medicine, 2015, 60, 8-31.	3.9	270
413	Epithelial–mesenchymal transition in prostatic disease. Future Oncology, 2015, 11, 3197-3206.	1.1	26
414	Prognostic Value of Prostaglandin-endoperoxide Synthase 2 Polymorphisms in Prostate Cancer Recurrence after Radical Prostatectomy. International Journal of Medical Sciences, 2016, 13, 696-700.	1.1	4
415	Diet, Lifestyles, Family History, and Prostate Cancer Incidence in an East Algerian Patient Group. BioMed Research International, 2016, 2016, 1-9.	0.9	11
416	Role of Genetic Polymorphisms in the Development and Prognosis of Sporadic and Familial Prostate Cancer. PLoS ONE, 2016, 11, e0166380.	1.1	4
417	Hereditary Prostate Cancer., 2016, , 141-147.		1
418	Primary prevention and early diagnosis of prostate cancer. European Journal of Cancer Prevention, 2016, 25, 137-141.	0.6	1
419	Leucine zipper, down regulated in cancer-1 gene expression in prostate cancer. Oncology Letters, 2016, 12, 2796-2800.	0.8	3
421	Familial prostate cancer. Seminars in Oncology, 2016, 43, 560-565.	0.8	49
422	Randomized trial finds that prostate cancer genetic risk score feedback targets prostateâ€specific antigen screening among atâ€risk men. Cancer, 2016, 122, 3564-3575.	2.0	4
424	Diffusion-Weighted Magnetic Resonance Imaging in Patients with Prostate Cancer Treated with Radiotherapy. Tumori, 2016, 102, 71-76.	0.6	9
426	Racial Disparity in Time between First Diagnosis and Initial Treatment of Prostate Cancer. Cancer Control, 2016, 23, 47-51.	0.7	30
428	Perceptions of Cancer Risk: Differences by Weight Status. Journal of Cancer Education, 2017, 32, 357-363.	0.6	5
429	Survival outcomes of <scp>C</scp> hinese metastatic prostate cancer patients following primary androgen deprivation therapy in relation to prostateâ€specific antigen nadir level. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e65-e71.	0.7	5
430	Association of <i>VDR</i> polymorphisms ( <i>Taq</i> I and <i>Bsm</i> I) with prostate cancer: a new meta-analysis. Journal of International Medical Research, 2017, 45, 3-10.	0.4	16
431	Smoking effect on oncological outcome among men with prostate cancer after radical prostatectomy. Japanese Journal of Clinical Oncology, 2017, 47, 453-457.	0.6	10

#	Article	IF	CITATIONS
433	The Search for the Missing Heritability of Prostate Cancer. European Urology, 2017, 72, 657-659.	0.9	8
434	Prostate cancer-related anxiety in long-term survivors after radical prostatectomy. Journal of Cancer Survivorship, 2017, 11, 800-807.	1.5	33
435	Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men. Journal of Urology, 2017, 197, S200-S207.	0.2	65
436	Outcomes of treatment in men with prostate cancer at the cancer centre Bahamas. Cancer Causes and Control, 2017, 28, 1285-1293.	0.8	3
437	Association Between the Asp312Asn, Lys751Gln, and Arg156Arg Polymorphisms in <i>XPD</i> and the Risk of Prostate Cancer. Technology in Cancer Research and Treatment, 2017, 16, 692-704.	0.8	8
439	Compatibility of Family History Cancer Guidelines With Meaningful Use Standards. JCO Clinical Cancer Informatics, 2017, 1, 1-9.	1.0	2
441	Cancer Detection with Prostate Zonal Segmentationâ€"A Review. Lecture Notes in Networks and Systems, 2018, , 829-835.	0.5	4
442	Metastatic Prostate Cancer in a RAD51C Mutation Carrier. Clinical Medicine and Research, 2018, 16, 69-72.	0.4	3
443	Genetic Susceptibility. Molecular Pathology Library, 2018, , 57-78.	0.1	0
444	<scp>ZEB</scp> 1â€mediated vasculogenic mimicry formation associates with epithelial–mesenchymal transition and cancer stem cell phenotypes in prostate cancer. Journal of Cellular and Molecular Medicine, 2018, 22, 3768-3781.	1.6	36
445	Landmarks in prostate cancer. Nature Reviews Urology, 2018, 15, 627-642.	1.9	78
446	The association of <i>BRCA1</i> and <i>BRCA2</i> mutations with prostate cancer risk, frequency, and mortality: A metaâ€analysis. Prostate, 2019, 79, 880-895.	1.2	100
447	Familial recurrence risk with varying amount of family history. Genetic Epidemiology, 2019, 43, 440-448.	0.6	0
449	Interest in, willingness-to-pay for and willingness-to-recommend genetic testing for prostate cancer among affected men after radical prostatectomy. Familial Cancer, 2019, 18, 221-230.	0.9	4
450	Discovery and Characterization of Cancer Genetic Susceptibility Alleles., 2020,, 323-336.e3.		1
451	Functional deficiency of DNA repair gene EXO5 results in androgen-induced genomic instability and prostate tumorigenesis. Oncogene, 2020, 39, 1246-1259.	2.6	8
453	Novel Predicted B-Cell Epitopes of PSMA for Development of Prostate Cancer Vaccine. International Journal of Peptide Research and Therapeutics, 2020, 26, 1523-1525.	0.9	6
454	Clinical and pathologic characteristics of familial prostate cancer in Asian population. Prostate, 2020, 80, 57-64.	1.2	5

#	Article	IF	Citations
455	BRCA2 gene mutation and prostate cancer risk. Journal of King Abdulaziz University, Islamic Economics, 2020, 41, 9-17.	0.5	13
456	Impact of a Changing Population Structure and Clustering of Cancer in Prostate Cancer Patients Depending on a First-Degree Family History. Urologia Internationalis, 2020, 104, 222-229.	0.6	3
457	Monitoring prostate cancer (PCa) with appraise the gene expression of PRUNE2, NCAPD3 and ASPA and their connection with age, family history and tumor stage. Gene Reports, 2020, 21, 100840.	0.4	2
458	Aptamer based recognition of cancer cells: Recent progress and challenges in bioanalysis. Talanta, 2020, 220, 121436.	2.9	49
459	Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland. International Journal of Cancer, 2020, 147, 2793-2800.	2.3	27
460	The role of fatal family history and mode of inheritance in prostate cancer for long-term outcomes following radical prostatectomy. World Journal of Urology, 2020, 38, 3091-3099.	1.2	8
461	Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men. Prostate Cancer and Prostatic Diseases, 2021, 24, 845-851.	2.0	11
463	Sleep disorders and prostate cancer prognosis. European Journal of Cancer Prevention, 2021, Publish Ahead of Print, .	0.6	3
464	Prostate Cancer Predisposition. Urologic Clinics of North America, 2021, 48, 283-296.	0.8	12
466	Recent Automatic Segmentation Algorithms of MRI Prostate Regions: A Review. IEEE Access, 2021, 9, 97878-97905.	2.6	21
467	The association of benign prostatic hyperplasia and cancer of the prostate. Cancer, 1992, 70, 291-301.	2.0	112
468	Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer, 1993, 71, 933-938.	2.0	478
469	Epidemiologic Characteristics of Prostate Cancer. Cancer, 1995, 75, 1766-1777.	2.0	69
470	Does the racial-ethnic variation in prostate cancer risk have a hormonal basis?. Cancer, 1995, 75, 1778-1782.	2.0	22
471	Familial Prostate Cancer., 2005, , 17-30.		1
472	Identification of Genetic Risk Factors for Prostate Cancer: Analytic Approaches Using Hereditary Prostate Cancer Families., 2010,, 203-228.		6
473	Cytogenetic and Molecular Genetic Aspects of Human Prostate Cancer: Primary and Metastatic. Advances in Experimental Medicine and Biology, 1992, 324, 45-75.	0.8	6
474	Epidemiology of prostate cancer and bladder cancer: an overview. Cancer Treatment and Research, 1996, 88, 1-11.	0.2	10

#	Article	IF	CITATIONS
475	Genetics and the common cancers. , 1996, , 208-226.		16
476	Familial prostate cancer and its management. , 1996, , 320-332.		2
477	The Molecular Basis of Prostate Carcinogenesis. , 2002, , 365-378.		1
478	Animal Models of Prostate Cancer. , 2008, , 639-649.		2
479	Biomarkers for Prostate Cancer Detection: Family-Based Linkage Analysis and Case–Control Association Studies. , 2009, , 261-277.		1
480	Epidemiology, Pathology, and Genetics of Prostate Cancer Among African Americans Compared with Other Ethnicities. Methods in Molecular Biology, 2009, 472, 439-453.	0.4	62
481	Epidemiology of Prostate Cancer. , 2007, 175, 1-8.		38
482	Cancer of the Prostate. , 2002, , 575-602.		1
483	Biochemistry of Prostatic Carcinoma. , 1994, , 169-237.		8
485	Cancer of the Prostate: Incidence in the USA. , 2003, , 115-119.		2
488	Original Articles. Journal of Urology, 1995, , 987-992.	0.2	30
489	Family History and the Risk of Prostatic Carcinoma in a High Risk Group of Urological Patients. Journal of Urology, 1995, 154, 404-406.	0.2	27
490	Familial Aspects of Prostate Cancer. Journal of Urology, 1995, , 2100-2102.	0.2	5
491	Clinical and Pathological Features of Hereditary Prostate Cancer. Journal of Urology, 1996, , 1841-1842.	0.2	3
492	Prostate Cancer in Nigerians. Journal of Urology, 1997, , 1340-1343.	0.2	3
493	Screening for Prostate Cancer in High Risk Populations. Journal of Urology, 2002, , 1980-1984.	0.2	2
494	Prostate cancer: epidemiology and risk factors. Current Opinion in Urology, 1998, 8, 375-380.	0.9	5
496	Occupational Risk Factors for Prostate Cancer: A Meta-analysis. Journal of Cancer Prevention, 2019, 24, 91-111.	0.8	47

#	Article	IF	CITATIONS
497	Polymorphisms in nucleotide excision repair genes and risk of primary prostate cancer in Chinese Han populations. Oncotarget, 2017, 8, 24362-24371.	0.8	21
498	Loss of endothelial cell-specific molecule 1 promotes the tumorigenicity and metastasis of prostate cancer cells through regulation of the TIMP-1/MMP-9 expression. Oncotarget, 2017, 8, 13886-13897.	0.8	19
499	Association of a common genetic variant in RNASEL and prostate cancer susceptibility. Oncotarget, 2017, 8, 75141-75150.	0.8	6
500	Family history of breast cancer increases the risk of prostate cancer: results from the EPICAP study. Oncotarget, 2018, 9, 23661-23669.	0.8	8
501	Systematic meta-analyses of gene-specific genetic association studies in prostate cancer. Oncotarget, 2016, 7, 22271-22284.	0.8	11
502	Prostate Cancer Incidence is Correlated to Total Meat Intake– a Cross-National Ecologic Analysis of 172 Countries. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2229-2239.	0.5	13
503	The diagnosis, management, treatment and costs of prostate cancer in England and Wales Health Technology Assessment, 1997, $1$ , .	1.3	56
504	Molecular MR Imaging of Prostate Cancer. Biomedicines, 2021, 9, 1.	1.4	29
505	Inappropriateness of prostate cancer screening by PSA in young Algerian farmers. Open Journal of Immunology, 2013, 03, 119-122.	0.5	2
506	Association between single nucleotide polymorphisms on chromosome 17q and the risk of prostate cancer in a Chinese population. Chinese Journal of Cancer, 2011, 30, 721-730.	4.9	9
507	Molecular Biology Underlying the Clinical Heterogeneity of Prostate Cancer: An Update. Archives of Pathology and Laboratory Medicine, 2009, 133, 1033-1040.	1.2	44
510	The Role of the IGF Axis in Epithelial-to-Mesenchymal Transition during the Progression of Prostate Cancer. Journal of Analytical Oncology, 2015, 4, 157-170.	0.1	1
511	8q24 rs4242382 Polymorphism is a Risk Factor for Prostate Cancer among Multi-Ethnic Populations: Evidence from Clinical Detection in China and a Meta-analysis. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8311-8317.	0.5	8
512	Epidemiology of and Risk Factors for Prostate Cancer. , 2000, , 19-45.		3
513	Public health assessment of genetic predisposition to cancer. , 2000, , 151-172.		1
514	Benign and Malignant Diseases of the Prostate. , 2001, , 806-816.		0
515	FamiliÃres Prostatakarzinom. , 2001, , 497-526.		0
516	Genetic Predisposition to Prostate Cancer. , 2002, , 279-285.		0

#	ARTICLE	IF	CITATIONS
517	A family with familial prostate cancer in which the proband was a hemodialysis patient Nihon Toseki Igakkai Zasshi, 2002, 35, 197-202.	0.2	0
518	Breast and Prostate Cancer: a Comparison of Two Common Endocrinologic Malignancies. , 2003, , 159-166.		1
519	Does Prostate Cancer Represent More than One Cancer?., 2003,, 29-34.		2
520	Genetic Changes and Their Prognostic Significance in Prostate Cancer. , 2003, , 101-112.		0
521	Hereditary Prostate Cancer and Genetic Risk. , 2004, , 57-69.		0
522	A Continuous Increase in Prevalence of Prostate Cancer in Korea and Its Causes. Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association, 2004, 47, 394.	0.1	1
523	Genetic Aspects of Urologic Malignancies. , 2004, , 205-240.		0
524	Prostatakarzinom. , 2004, , 1233-1266.		0
525	Defining an Optimum PSA-Based Screening Strategy for Young Men., 2004,, 37-56.		0
526	Prostate Cancer Prevention., 2005,, 185-203.		1
527	Effects of Dietary Habits on the Serum Isoflavones Levels. Korean Journal of Urology, 2006, 47, 773.	0.2	0
528	Is familie-onderzoek aan te bevelen bij familiair voorkomen van prostaatcarcinoom?., 2006,, 3438-3440.		0
529	The Molecular Pathogenesis and Pathophysiology of Prostate Cancer. Translational Medicine Series, 2006, , 1-25.	0.0	0
530	Prostate gland disease. , 2007, , 617-629.		0
531	Epidemiology, Pathology and Pathogenesis. , 2008, , 451-469.		13
533	Family History: A Bridge Between Genomic Medicine and Disease Prevention. , 2009, , 481-492.		1
534	Familial Prostate Cancer in Three Brothers. Korean Journal of Urology, 2009, 50, 195.	1.2	1
535	Inherited Susceptibility of Aggressive Prostate Cancer. , 2010, , 289-315.		0

#	Article	IF	Citations
536	Mechanisms of Carcinogenesis in Prostate Cancer. , 2010, , 295-304.		0
538	Cytotoxicity of PP(Arg)(2)- and Hp(Arg)(2)-mediated photodynamic therapy and early stage of apoptosis induction in prostate carcinoma in vitro Acta Biochimica Polonica, 2011, 58, .	0.3	1
539	High-Intensity Focused Ultrasound (HIFU) - An Alternative Choice in Prostate Cancer Treatment. , 0, , .		0
540	Predicting High-Risk Disease Using Serum and DNA Biomarkers. , 2012, , 35-54.		0
541	Hereditary Prostate Cancer and Genetic Risk. , 2012, , 79-101.		0
542	Molecular Genetics and Cancer Biology. , 2012, , 530-567.e16.		0
543	Reproductive System., 2014,, 89-136.		0
544	Indicators incidence of prostate cancer in the Republic of Serbia and other countries of the world. Zdravstvena Zastita, 2014, 43, 7-18.	0.0	0
545	Discovery and Characterization of Cancer Genetic Susceptibility Alleles. , 2014, , 309-321.e3.		0
547	Epidemiologische und morphogenetische Aspekte des Prostatakarzinoms. , 1992, , 3-16.		0
548	Cancer of the prostate. JAMA - Journal of the American Medical Association, 1992, 268, 3196b-3196.	3.8	1
549	Familial Factors in Cancer of the Genitourinary Tract. Recent Results in Cancer Research, 1994, 136, 306-321.	1.8	O
551	Conservative Treatment of Localised Prostate Cancer. , 1994, , 175-195.		0
552	Benign and Malignant Prostatic Neoplasms: Human Studies. , 1994, 49, 293-331.		7
553	The genetics of prostate cancer. Cancer Biology and Medicine, 1995, , 67-83.	0.1	0
554	Andere für das Prostata-Screening interessante Marker. , 1995, , 149-165.		0
556	The Epidemiology and Etiology of Prostate Cancer. Medical Radiology, 1996, , 1-11.	0.0	3
557	Screening for Prostate Cancer. Focus on Cancer, 1996, , 117-135.	0.1	2

#	Article	IF	Citations
558	Cancers of the Urinary Tract., 1998,, 695-722.		1
559	Malignancy of the Prostate Gland. , 1998, , 195-205.		0
560	Genetic Counseling and Genetic Testing for Cancer Risk Assessment. Clinical Obstetrics and Gynecology, 1998, 41, 141-156.	0.6	2
561	BIOLOGICAL AGGRESSIVENESS OF HEREDITARY PROSTATE CANCER. Journal of Urology, 1998, , 660-663.	0.2	4
563	Evaluation of the Relationship Between Prostate-Specific Antigen and Prostate Size and Also PSA and BMI in Subjects Referred to the Check-up Clinic of Razavi Hospital. Razavi International Journal of Medicine, 2014, 2, .	0.1	0
564	Epidemiology, Screening, Pathology and Pathogenesis. , 2015, , 677-695.		o
565	Prostate Cancer Among Asian Americans. , 2016, , 161-185.		0
566	The Molecular Pathogenesis and Pathophysiology of Prostate Cancer. , 2016, , 19-44.		О
567	Association of CYP17 Gene Polymorphism with Benign Prostatic Hyperplasia. Scholars Journal of Applied Medical Sciences, 2016, 4, 2630-2635.	0.0	1
569	Score genético predice agresividad del cáncer de próstata Ars Medica, 2018, 43, 17-24.	0.1	1
570	Estilo de vida y agresividad del cáncer de próstata Ars Medica, 2018, 43, 25-32.	0.1	1
571	Benign and Malignant Diseases of the Prostate. , 2020, , 1-32.		O
572	Benign and Malignant Diseases of the Prostate. , 2020, , 651-682.		0
573	Genetische Einflussfaktoren des Krebsrisikos. Springer Reference Medizin, 2020, , 1-7.	0.0	0
575	Screening for prostate cancer. Western Journal of Medicine, 1995, 162, 235-42.	0.3	3
576	Prostate cancer: 3. Individual risk factors. Cmaj, 1998, 159, 807-13.	0.9	25
577	Prostate cancer: risk assessment and diagnostic approaches. Reviews in Urology, 2001, 3 Suppl 2, S31-8.	0.9	0
578	Hereditary aspects of prostate cancer. Cmaj, 1995, 153, 895-900.	0.9	3

#	Article	IF	CITATIONS
579	The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer. Transactions of the American Clinical and Climatological Association, 2000, 111, 201-41.	0.9	25
580	The changing pattern of prostate cancer in Nigerians: current status in the southeastern states. Journal of the National Medical Association, 2002, 94, 619-27.	0.6	36
581	Radical prostatectomy: lower rates among African-American men. Journal of the National Medical Association, 1996, 88, 589-94.	0.6	42
582	Increased incidence of prostate cancer in Nigerians. Journal of the National Medical Association, 1999, 91, 159-64.	0.6	66
583	Assessment of possible association between rs3787016 and prostate cancer risk in Serbian population. International Journal of Clinical and Experimental Medicine, 2013, 6, 57-66.	1.3	9
584	Prostaglandin-endoperoxide synthase 2 (PTGS2) rs20417 polymorphism and prostate cancer risk: a meta analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 20454-62.	1.3	3
585	Systematic Analysis of Free-Text Family History in Electronic Health Record. AMIA Summits on Translational Science Proceedings, 2017, 2017, 104-113.	0.4	12
586	Novel and Efficient Method for Solid Phase Synthesis of Urea-Containing Peptides Targeting Prostate Specific Membrane Antigen (PSMA) in Comparison with Current Methods. Iranian Journal of Pharmaceutical Research, 2018, 17, 917-926.	0.3	3
587	Recurrence of prostate cancer after HIFU. Proposal of a novel predictive index. Acta Biomedica, 2018, 89, 220-226.	0.2	9
588	How is the association between urinary prostate cancer antigen 3 (PCA3) levels and Gleason scores in patients suspicious of prostate cancer?. International Journal of Physiology, Pathophysiology and Pharmacology, 2019, 11, 283-288.	0.8	1
589	Association of a common genetic variant (insertion/deletion) in <i>ACE</i> gene with prostate cancer susceptibility in a Tunisian population. Journal of Clinical Laboratory Analysis, 2022, 36, e24129.	0.9	6
590	In vitro and in vivo anticancer effect of pH-responsive paclitaxel-loaded niosomes. Journal of Materials Science: Materials in Medicine, 2021, 32, 147.	1.7	23
591	Racial Differences in Prostate Cancer Characteristics and Cancer-Specific Mortality: An Overview. World Journal of Men?s Health, 2022, 40, 217.	1.7	19
593	Hormone-Naïve Metastatic Prostate Cancer: A Presentation of 110 Cases in a Urology Center in the City of Douala, Cameroon. Open Journal of Urology, 2022, 12, 83-97.	0.0	0
594	Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers. Frontiers in Chemistry, 2022, 10, 830133.	1.8	4
597	Role of single nucleotide polymorphisms of the HSD3B1 gene (rs6203 and rs33937873) in the prediction of prostate cancer risk. Molecular Medicine Reports, 2022, 26, .	1,1	0
598	Resistance to prostate cancer treatments. IUBMB Life, 2023, 75, 390-410.	1.5	4
599	Prostate Cancer: Risk Factors and Outcome Indicators. Surgical Science, 2022, 13, 381-400.	0.1	0

#	ARTICLE	IF	CITATIONS
600	Variants in HOXB13, G132E and F127C, Are Associated With Prostate Cancer Risk in Japanese Men. Cancer Diagnosis & Prognosis, 2022, 2, 542-548.	0.3	0
601	Initial outcomes and insights from a novel highâ€risk prostate cancer screening clinic. Prostate, 0, , .	1.2	O
603	Polygenic risk score for tumor aggressiveness and early-onset prostate cancer in Asians. Scientific Reports, 2023, $13$ , .	1.6	0
604	Nuklearmedizin der Prostata und des Ãußeren Genitale. Springer Reference Medizin, 2022, , 1-16.	0.0	0
606	Nuklearmedizin der Prostata und des Ãußeren Genitale. Springer Reference Medizin, 2023, , 1487-1502.	0.0	0